<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PFIZERPEN- penicillin g potassium powder, for solution </strong><br>Roerig<br></p></div>
<h1>Buffered<br>	PFIZERPEN<br> (penicillin G potassium)<br>	for Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin G Potassium and other antibacterial drugs, Penicillin G Potassium for Injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Buffered Pfizerpen (penicillin G potassium) for Injection is a sterile, pyrogen-free powder for reconstitution. Buffered Pfizerpen for Injection is an antibacterial agent for intramuscular, continuous intravenous drip, intrapleural or other local infusion, and intrathecal administration.</p>
<p>Each million units contains approximately 6.8 milligrams of sodium (0.3 mEq) and 65.6 milligrams of potassium (1.68 mEq). Buffered Penicillin G Potassium for Injection, USP is supplied in vials equivalent to 5,000,000 units (5 million units) or 20,000,000 units (20 million units) of penicillin G as the potassium salt.</p>
<p>Chemically, Pfizerpen is monopotassium 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo (3.2.0) heptane-2-carboxylate. It has a molecular weight of 372.48 and the following chemical structure:</p>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320&amp;name=pfizerpen-01.jpg"></td></tr>
<tr><td align="center">Formula<br>C<span class="Sub">16</span>H<span class="Sub">17</span>KN<span class="Sub">2</span>O<span class="Sub">4</span>S</td></tr>
</tbody>
</table>
<p>Penicillin G potassium is a colorless or white crystal, or a white crystalline powder which is odorless, or practically so, and moderately hygroscopic. Penicillin G potassium is very soluble in water. The pH of the reconstituted product is between 6.0–8.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="cp"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Aqueous penicillin G is rapidly absorbed following both intramuscular and subcutaneous injection. Initial blood levels following parenteral administration are high but transient. Penicillins bind to serum proteins, mainly albumin. Therapeutic levels of the penicillins are easily achieved under normal circumstances in extracellular fluid and most other body tissues. Penicillins are distributed in varying degrees into pleural, pericardial, peritoneal, ascitic, synovial, and interstitial fluids. Penicillins are excreted in breast milk. Penetration into the cerebrospinal fluid, eyes, and prostate is poor. Penicillins are rapidly excreted in the urine by glomerular filtration and active tubular secretion, primarily as unchanged drug. Approximately 60 percent of the total dose of 300,000 units is excreted in the urine within this 5-hour period. For this reason, high and frequent doses are required to maintain the elevated serum levels desirable in treating certain severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in individuals with normal kidney function. In neonates and young infants, and in individuals with impaired kidney function, excretion is considerably delayed.</p>
<p>After an intravenous infusion of penicillin G, peak serum concentrations are attained immediately after completion of the infusion. In a study of ten patients administered a single 5 million unit dose of penicillin G intravenously over 3–5 minutes, the mean serum concentrations were 400 mcg/mL, 273 mcg/mL and 3.0 mcg/mL at 5–6 minutes, 10 minutes and 4 hours after completion of the injection, respectively. In a separate study, five healthy adults were administered one million units of penicillin G intravenously, either as a bolus over 4 minutes or as an infusion over 60 minutes. The mean serum concentration eight minutes after completion of the bolus was 45 mcg/mL and eight minutes after completion of the infusion was 14.4 mcg/mL. The mean β-phase serum half-life of penicillin G administered by the intravenous route in ten patients with normal renal function was 42 minutes, with a range of 31–50 minutes.</p>
<p>The clearance of penicillin G in normal individuals is predominantly via the kidney. The renal clearance, which is extremely rapid, is the result of glomerular filtration and active tubular transport, with the latter route predominating. Urinary recovery is reported to be 58–85% of the administered dose. Renal clearance of penicillin is delayed in premature infants, neonates and in the elderly due to decreased renal function. The serum half-life of penicillin G correlates inversely with age and clearance of creatinine and ranges from 3.2 hours in infants 0 to 6 days of age to 1.4 hours in infants 14 days of age or older.</p>
<p>Nonrenal clearance includes hepatic metabolism and, to a lesser extent, biliary excretion. The latter routes become more important with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Probenecid blocks the renal tubular secretion of penicillin. Therefore, the concurrent administration of probenecid prolongs the elimination of penicillin G and, consequently, increases the serum concentrations.</p>
<p>Penicillin G is distributed to most areas of the body including lung, liver, kidney, muscle, bone and placenta. In the presence of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, levels of penicillin in <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, middle ear, pleural, peritoneal and synovial fluids are sufficient to inhibit most susceptible bacteria. Penetration in the eye, brain, cerebrospinal fluid (CSF) or prostate is poor in the absence of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. With inflamed meninges, the penetration of penicillin G into the CSF improves, such that the CSF/serum ratio is 2–6%. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> also enhances its penetration into the pericardial fluid. Penicillin G is actively secreted into the bile resulting in levels at least 10 times those achieved simultaneously in serum. Penicillin G penetrates poorly into human polymorphonuclear leukocytes.</p>
<p>In the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, the β-phase serum half-life of penicillin G is prolonged. β-phase serum half-lives of one to two hours were observed in azotemic patients with serum creatinine concentrations &lt;3 mg/100 mL and ranged as high as 20 hours in anuric patients. A linear relationship, including the lowest range of renal function, is found between the serum elimination rate constant and renal function as measured by creatinine clearance.</p>
<p>In patients with altered renal function, the presence of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> further alters the elimination of penicillin G. In one study, the serum half-lives in two anuric patients (excreting &lt;400 mL urine/day) were 7.2 and 10.1 hours. A totally anuric patient with terminal <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> had a penicillin half-life of 30.5 hours, while another patient with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> and liver disease had a serum half-life of 16.4 hours. The dosage of penicillin G should be reduced in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, with additional modifications when <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> accompanies the <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Hemodialysis has been shown to reduce penicillin G serum levels. </p>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell wall peptidoglycan rendering the cell wall osmotically unstable. It is not active against the penicillinase-producing bacteria, which include many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of staphylococci or against organisms resistant to beta-lactams because of alterations in the penicillin-binding proteins, such as methicillin-resistant staphylococci. Penicillin G is highly active <span class="Italics">in vitro</span> against streptococci (groups A, B, C, G, H, L and M) and <span class="Italics">Neisseria meningitidis</span>.</p>
<p>Other organisms susceptible to penicillin G are <span class="Italics">N. gonorrhoeae</span>, <span class="Italics">Corynebacterium diphtheriae</span>, <span class="Italics">Bacillus anthracis</span>, <span class="Italics">Clostridium </span>spp., <span class="Italics">Actinomyces</span> species, "<span class="Italics">Spirillum minus</span>", <span class="Italics">Streptobacillus moniliformis, </span><span class="Italics">Listeria monocytogenes</span> and <span class="Italics">Leptospira</span> spp.; <span class="Italics">Treponema pallidum</span> is extremely sensitive to the bactericidal action of penicillin G.</p>
<p>Some species of gram-negative bacilli were previously considered susceptible to very high intravenous doses of penicillin G (up to 80 million units/day) including some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli, Proteus mirabilis, <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> spp. and <span class="Italics">Shigella</span> spp.; <span class="Italics">Enterobacter aerogenes</span> (formerly <span class="Italics">Aerobacter aerogenes</span>) and <span class="Italics">Alcaligenes faecalis</span>. Penicillin G is no longer considered a drug of choice for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by these organisms.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Susceptibility Test Methods</h3>
<p class="First">When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1.1"></a><p></p>
<h4>Dilution Techniques</h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on dilution method <span class="Sup">1, 2, 3</span> (broth or agar dilution) or equivalent using standardized inoculum and concentrations of penicillin. The MIC values should be interpreted according to the criteria in Table 1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1.2"></a><p></p>
<h4>Diffusion Techniques</h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure <span class="Sup">2, 4</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 10 units of penicillin to test the susceptibility of microorganisms to penicillin. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for penicillin. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 10 unit penicillin disk should be interpreted according to the following criteria in Table 1.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Susceptibility Test Interpretive Criteria for Penicillin</span></caption>
<col align="left" valign="top" width="17%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="14%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="3">MIC (mcg/mL)</th>
<th class="Rrule" align="center" colspan="3">Disk Diffusion (zone diameter in mm)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Pathogen</th>
<th class="Rrule" align="center">Susceptible<br>(S)</th>
<th class="Rrule" align="center">Intermediate<br>(I)</th>
<th class="Rrule" align="center">Resistant<br>(R)</th>
<th class="Rrule" align="center">Susceptible<br>(S)</th>
<th class="Rrule" align="center">Intermediate<br>(I)</th>
<th class="Rrule" align="center">Resistant<br>(R)</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Organisms for which no values for disk susceptibility appear cannot be reliably tested with this method.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Penicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of staphylococci produce β-lactamase. An induced β-lactamase test should be performed on all <span class="Italics">S. aureus</span> isolates for which the penicillin MIC is ≤ 0.12 mcg/mL or zone diameter is ≥ 29 mm before reporting as penicillin susceptible. Rare isolates of staphylococci that contains genes for β-lactamase production may not produce a positive induced β-lactamase test. For serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> requiring penicillin therapy, laboratories should perform MIC tests and induced β-lactamase testing on all subsequent isolates from the same patient.<span class="Sup">2</span>
</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>A positive <span class="Italics">N. gonorrhoeae</span> β-lactamase test predicts one form of resistance to penicillin. <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> with chromosomally mediated resistance can be detected only by agar dilution or disk diffusion susceptibility test methods.<span class="Sup">2</span> Isolates with zone diameters ≤ 19 mm generally produced β-lactamase.<span class="Sup">2,4</span>
</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>The current absence of resistant isolates precludes defining results other than "Susceptible". Isolates yielding results suggestive of "Non-susceptible" should be submitted to a reference laboratory for further testing.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Susceptibility testing of penicillins for treatment of β-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> need not be performed routinely, because non-susceptible isolates are extremely rare in any β-hemolytic streptococcus and have not been reported from <span class="Italics">Streptococcus pyogenes</span>. Any β-hemolytic streptococcal isolate found to be non-susceptible to penicillin should be re-identified, retested, and, if confirmed, submitted to a public health authority.<span class="Sup">2,4</span>
</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>
<span class="Italics">B. anthracis</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> may contain inducible β-lactamases. <span class="Italics">In vitro</span> penicillinase induction studies suggest that penicillin MICs may increase during therapy. However, β-lactamase testing of clinical isolates of <span class="Italics">B. anthracis </span>is unreliable and should not be performed.<span class="Sup">3</span>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Italics">Staphylococcus </span>spp.</td>
<td class="Rrule" align="center">≤0.12<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">≥0.25</td>
<td class="Rrule" align="center">≥29<a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">≤28</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">Neisseria Gonorrhoeae</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">≤0.06</td>
<td class="Rrule" align="center">0.12 – 1</td>
<td class="Rrule" align="center">≥2</td>
<td class="Rrule" align="center">≥47</td>
<td class="Rrule" align="center">27 – 46</td>
<td class="Rrule" align="center">≤26</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Listeria Monocytogenes</span></td>
<td class="Rrule" align="center">≤2<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">Streptococcus pneumoniae </span><span class="Bold"> (</span><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>)</td>
<td class="Rrule" align="center">≤0.06</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">≥0.12</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">Streptococcus pneumoniae</span> (non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>)</td>
<td class="Rrule" align="center">≤2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">≥8</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">Streptococcus </span>spp.,<br>Beta-hemolytic Group<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">≤0.12<a href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">≥24<a href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">Streptococcus </span>spp.,<br>Viridans Group</td>
<td class="Rrule" align="center">≤0.12</td>
<td class="Rrule" align="center">0.25–2</td>
<td class="Rrule" align="center">≥4</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">
<span class="Italics">Bacillus anthracis</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td class="Rrule" align="center">≤0.12</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">≥0.25</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1.3"></a><p></p>
<h4>Quality Control</h4>
<p class="First">Standardized susceptibility test procedures require the use of laboratory control microorganisms to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard penicillin powder should provide MIC values provided below. For the diffusion technique, the 10 unit penicillin disk should provide the following zone diameters with the quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2. In Vitro Susceptibility Test Quality Control Ranges for Penicillin</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="32%">
<col align="center" valign="top" width="35%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Organism (ATTC #)</th>
<th class="Rrule" align="center">MIC range mcg/mL</th>
<th class="Rrule" align="center">Disk Diffusion range (mm)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Using agar dilution method only. No criteria for broth microdilution are available.<span class="Sup">2</span>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Italics">Staphylococcus aureus </span>(29213)</td>
<td class="Rrule" align="center">0.25 – 2</td>
<td class="Rrule" align="center">Not applicable</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">Staphylococcus aureus (</span>25923)</td>
<td class="Rrule" align="center">Not applicable</td>
<td class="Rrule" align="center">26 – 37</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">Streptococcus pneumoniae </span>(49619)</td>
<td class="Rrule" align="center">0.25 – 1</td>
<td class="Rrule" align="center">24 – 30</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">
<span class="Italics">Neisseria gonorrhoeae </span>(49226)</td>
<td class="Rrule" align="center">0.25 – 1<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="center">26 – 34</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="iau"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Therapy</h2>
<p class="First">Penicillin G Potassium for Injection, USP is indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below.</p>
<p>Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and to determine their susceptibility to penicillin G.</p>
<p>Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued.</p>
<table width="75%">
<col align="left" valign="top" width="45%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="45%">
<thead><tr class="First Last">
<th align="center">CLINICAL INDICATION</th>
<th align="left"></th>
<th align="center">INFECTING ORGANISM</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span>, <span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">empyema</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span></td>
<td align="left"></td>
<td align="left">
<span class="Italics">Streptococcus pyogenes</span> (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, <span class="Italics">Streptococcus pneumoniae</span> and <span class="Italics">Staphylococcus </span>species (non-penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span></td>
<td align="left"></td>
<td align="left">
<span class="Italics">Bacillus anthracis</span><br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> (cervico-facial disease and thoracic and abdominal disease)</td>
<td align="left"></td>
<td align="left">
<span class="Italics">Actinomyces israelii</span><br><br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> (adjunctive therapy to antitoxin), <span class="product-label-link" type="condition" conceptid="433696" conceptname="Gas gangrene">gas gangrene</span>, and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> (adjunctive therapy to human <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> immune globulin)<br>
</td>
<td align="left"></td>
<td align="left">
<span class="Italics">Clostridium</span> species</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> (adjunctive therapy to antitoxin and prevention of the carrier state)<br>
</td>
<td align="left"></td>
<td align="left"><span class="Italics">Corynebacterium diphtheriae</span></td>
</tr>
<tr>
<td align="left">Erysipelothrix <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span><br>
</td>
<td align="left"></td>
<td align="left"><span class="Italics">Erysipelothrix rhusiopathiae</span></td>
</tr>
<tr>
<td align="left">Fusospirochetosis (severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the oropharynx [Vincent's], lower respiratory tract and genital area)<br>
</td>
<td align="left"></td>
<td align="left">
<span class="Italics">Fusobacterium </span>species and spirochetes</td>
</tr>
<tr>
<td align="left">Listeria <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span><br>
</td>
<td align="left"></td>
<td align="left"><span class="Italics">Listeria monocytogenes</span></td>
</tr>
<tr>
<td align="left">Pasteurella <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> and <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span><br>
</td>
<td align="left"></td>
<td align="left"><span class="Italics">Pasteurella multocida</span></td>
</tr>
<tr>
<td align="left">Haverhill <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></td>
<td align="left"></td>
<td align="left">
<span class="Italics">Streptobacillus moniliformis</span><br>
</td>
</tr>
<tr>
<td align="left">Rat bite <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></td>
<td align="left"></td>
<td align="left">
<span class="Italics">Spirillum minus</span> or<span class="Italics"> Streptobacillus moniliformis</span>
</td>
</tr>
<tr>
<td align="left">Disseminated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td align="left"></td>
<td align="left">
<span class="Italics">Neisseria gonorrhoeae </span>(Penicillin-susceptible)<br>
</td>
</tr>
<tr>
<td align="left">Syphillis (congenital and neurosyphilis)</td>
<td align="left"></td>
<td align="left">
<span class="Italics">Treponema pallidum</span><br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438338" conceptname="Meningococcal meningitis">Meningococcal meningitis</span> and/or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span></td>
<td align="left"></td>
<td align="left">
<span class="Italics">Neisseria meningitidis</span><br>
</td>
</tr>
<tr class="Last">
<td align="left">Gram-negative bacillary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremias</span>)<br><span class="Bold">Penicillin G is not the drug of choice in the treatment of Gram-negative bacillary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </span>
</td>
<td align="left"></td>
<td align="left">Gram-negative bacillary organisms (<span class="Italics">i.e</span>. <span class="Italics">Enterobacteriaceae)</span>
</td>
</tr>
</tbody>
</table>
<p>To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium and other antibacterial drugs, Penicillin G Potassium should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">A history of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reaction to any penicillin is a contraindication.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with penicillin G, careful inquiry should be made concerning previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to penicillins, cephalosporins, or other allergens. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, penicillin G should be discontinued and appropriate therapy instituted. Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated.</p>
<p><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Penicillin G Potassium for Injection, USP, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Penicillin should be used with caution in individuals with histories of significant allergies and/or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (see <span class="Bold"><a href="#Warnings">Warnings</a></span>). Whenever <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy. Penicillin G Potassium for Injection, USP by the intravenous route in high doses (above 10 million units) should be administered slowly because of the potential adverse effects of <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> from the potassium content of the penicillin. Penicillin G Potassium for Injection, USP contains 1.68 mEq potassium and 0.3 mEq of sodium per million units. The use of antibiotics may promote overgrowth of nonsusceptible organisms, including fungi. Indwelling intravenous catheters encourage <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span>. Should <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occur, appropriate measures should be taken. When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy.</p>
<p>Prescribing Penicillin G Potassium for Injection, USP in the absence of proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Penicillin G Potassium for Injection, USP should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Penicillin G Potassium for Injection, USP is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Penicillin G Potassium for Injection, USP or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Periodic assessment of organ system function, including frequent evaluation of electrolyte balance, hepatic, renal and hematopoietic systems, and cardiac and vascular status should be performed during prolonged therapy with high doses of intravenous penicillin G (see <span class="Bold"><a href="#AR"> Adverse Reactions</a></span>). If any impairment of function is suspected or known to exist, a reduction in the total dosage should be considered (see <span class="Bold"><a href="#DAA"> Dosage and Administration</a></span>). In suspected <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span>, proper laboratory studies, including susceptibility tests should be performed. All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to Group A beta-hemolytic streptococci should be treated for at least 10 days.</p>
<p>Patients being treated for gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> before receiving penicillin. All cases of penicillin treated <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> should receive adequate follow-up including clinical and serological examinations. The recommended follow-up varies with the stage of <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> being treated.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Bacteriostatic antibacterials (<span class="Italics">i.e</span>., chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. This has been documented <span class="Italics">in vitro</span>; however, the clinical significance of this interaction is not well-documented.</p>
<p>Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. Other drugs may compete with penicillin G for renal tubular secretion and thus prolong the serum half-life of penicillin. These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">After treatment with penicillin G, a false-positive reaction for glucose in the urine may occur with Benedict's solution, Fehling's solution or Clinitest® tablet, but not with the enzyme-based tests, such as Clinistix® and Tes-Tape®.</p>
<p>Penicillin G has been associated with pseudoproteinuria by certain test methods.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long term animal studies have been conducted with this drug.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Penicillins are excreted in human milk. Caution should be exercised when penicillins are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="precautions-ped-use"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Incompletely developed renal function in newborns may delay elimination of penicillin; therefore, appropriate reductions in the dosage and frequency of administration should be made in these patients. All newborns treated with penicillins should be monitored closely for clinical and laboratory evidence of toxic or adverse effects (see <span class="Bold"><a href="#precautions">Precautions</a></span>).</p>
<p>Pediatric doses are generally determined on a weight basis and should be calculated for each patient individually. Recommended guidelines for pediatric dosages are presented in <span class="Bold">Dosage and Administration</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of penicillin G Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
<p>Penicillin G for Injections contains 6.8 mg (0.3 mEq) of sodium per million units. At the usual recommended doses of 10 to 20 million units per day patients would receive between 68 and 136 mg/day (3 and 6 mEq) of sodium per day. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Body as a whole</h2>
<p class="First">The Jarisch-Herxheimer reaction is a systemic reaction, that may occur after the initiation of penicillin therapy in patients with <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> or other spirochetal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="Italics">i.e</span>., <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> and <span class="product-label-link" type="condition" conceptid="440637" conceptname="Relapsing fever">Relapsing fever</span>). The reaction begins one or two hours after initiation of therapy and disappears within 12 to 24 hours. It is characterized by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, exacerbation of cutaneous lesions, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, vasodilation with <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and mild <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The pathogenesis of the Herxheimer reaction may be due to the release from the spirochetes of heat-stable pyrogen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></h2>
<p class="First">The reported incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to all penicillins ranges from 0.7 to 10 percent in different studies (see <span class="Bold"><a href="#warnings"> Warnings</a></span>). Sensitization is usually the result of previous treatment with a penicillin, but some individuals have had immediate reactions when first treated. In such cases, it is postulated that prior exposure to penicillin may have occurred via trace amounts present in milk or vaccines.</p>
<p>Two types of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to penicillin are noted clinically – immediate and delayed.</p>
<p>Immediate reactions usually occur within 20 minutes of administration and range in severity from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> to <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see <span class="Bold"><a href="#Warnings"> Warnings</a></span>). Such immediate <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> are very rare and usually occur after parenteral therapy, but a few cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported following oral therapy. Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and, occasionally, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>.</p>
<p>Delayed reactions to penicillin therapy usually occur within 1–2 weeks after initiation of therapy. Manifestations include <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like symptoms, i.e., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and various <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, ranging from maculopapular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> to <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span> has been observed in individuals who prepare penicillin solutions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Gastrointestinal system</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with the onset occurring during or after penicillin G treatment. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, black or hairy tongue, and other symptoms of <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> may occur, especially during oral therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Hematologic system</h2>
<p class="First">Reactions include <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, which resolves after penicillin therapy is discontinued; Coombs-positive hemolytic <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anaemia</span>, an uncommon reaction, occurs in patients treated with intravenous penicillin G in doses greater than 10 million units/day and who have previously received large doses of the drug; and with large doses of penicillin, a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis can occur secondary to platelet dysfunction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AR-metabolic"></a><a name="section-8.5"></a><p></p>
<h2>Metabolic</h2>
<p class="First">Penicillin G Potassium, USP (1 million units contains 1.7 mEq of potassium ion) may cause serious and even fatal <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, <span class="Italics">i.e</span>., <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, when given intravenously in large doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>Nervous system</h2>
<p class="First">Neurotoxic reactions including <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, myoclonic <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitches</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> have been reported following the administration of massive intravenous doses, and are more likely in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2>Urogenital system</h2>
<p class="First">Renal tubular damage and interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> have been associated with large intravenous doses of penicillin G. Manifestations of this reaction may include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, eosinophiluria, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and a rise in serum urea nitrogen.</p>
<p>Discontinuation of penicillin G results in resolution in the majority of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.8"></a><p></p>
<h2>Local reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> may occur, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the injection site has been reported with intravenous administration.</p>
<p>To report SUSPECTED ADVERSE EVENTS, contact (<span class="Italics">insert name of manufacturer</span>) at (<span class="Italics">insert manufacturer's phone number</span>) or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="overdosage"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Dose related toxicity may arise with the use of massive doses of intravenous penicillins (40 to 100 million units per day), particularly in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold"><a href="#Precautions">Precautions</a></span>). The manifestations may include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, multifocal <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> is also possible (see <span class="Bold"><a href="#AR-metabolic"> Adverse Reactions-Metabolic</a></span>).</p>
<p>In case of overdosage, discontinue penicillin, treat symptomatically and institute supportive measures as required. If necessary, hemodialysis may be used to reduce blood levels of Penicillin G, although the degree of effectiveness of this procedure is questionable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DAA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Buffered Penicillin G Potassium for Injection, USP may be given intravenously or intramuscularly. The usual dose recommendations are as follows:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Adult patients</h2>
<table width="75%">
<col align="left" valign="top" width="45%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="45%">
<thead><tr class="First Last">
<th align="center">CLINICAL INDICATION</th>
<th align="left"></th>
<th align="center">DOSAGE</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Because of its short half-life, Penicillin G is administered in divided doses, usually every 4–6 hours with the exception of <span class="product-label-link" type="condition" conceptid="438338" conceptname="Meningococcal meningitis">meningococcal meningitis</span>/<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="Italics">i.e.</span>, every 2 hours.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of streptococci (including <span class="Italics">S. pneumoniae</span>)<br><br>-<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">empyema</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> and <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span></td>
<td align="left"></td>
<td align="left">12 to 24 million units/day depending on the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and its severity administered in equally divided doses every 4–6 hours.</td>
</tr>
<tr>
<td align="left">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of staphylococci<br><br>-<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">empyema</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> and <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span></td>
<td align="left"></td>
<td align="left">5 to 24 million units/day depending on the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and its severity administered in equally divided doses every 4–6 hours.</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span></td>
<td align="left"></td>
<td align="left">Minimum of 8 million units/day in divided doses every 6 hours. Higher doses may be required depending on susceptibility of organism.</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span><br>  Cervicofacial disease<br>  Thoracic and abdominal disease<br>
</td>
<td align="left"></td>
<td align="left">
<br>1 to 6 million units/day<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a><br>10 to 20 million units/day<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4211252" conceptname="Clostridial infection">Clostridial infections</span><br>  <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> (adjunctive therapy to antitoxin)<br>  <span class="product-label-link" type="condition" conceptid="433696" conceptname="Gas gangrene">Gas gangrene</span> (debridement and/or surgery as indicated)<br>  <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> (adjunctive therapy to human <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> immune globulin)<br>
</td>
<td align="left"></td>
<td align="left">
<br>20 million units/day<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> (adjunctive therapy to antitoxin and for the prevention of the carrier state)<br>
</td>
<td align="left"></td>
<td align="left">2 to 3 million units/day in divided doses for 10–12 days<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Erysipelothrix <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span><br>
</td>
<td align="left"></td>
<td align="left">12 to 20 million units/day for 4–6 weeks<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Fusospirochetosis (severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the oropharynx [Vincent's], lower respiratory tract and genital area)<br>
</td>
<td align="left"></td>
<td align="left">5 to 10 million units/day<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Listeria <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><br>  <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span><br>  <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span><br>
</td>
<td align="left"></td>
<td align="left">
<br>15 to 20 million units/day for 2 weeks<a href="#footnote-8" class="Sup">*</a><br>15 to 20 million units/day for 4 weeks<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Pasteurella <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> and <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span><br>
</td>
<td align="left"></td>
<td align="left">4 to 6 million units/day for 2 weeks<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Haverhill <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; Rat-bite <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span><br>
</td>
<td align="left"></td>
<td align="left">12 to 20 million units/day for 3–4 weeks<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Disseminated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, such as <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, etc., caused by penicillin – susceptible organisms<br>
</td>
<td align="left"></td>
<td align="left">10 million units/day<a href="#footnote-8" class="Sup">*</a>; duration depends on the type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> (neurosyphilis)</td>
<td align="left"></td>
<td align="left">12 to 24 million units/day, as 2–4 MU every 4 hours for 10–14 days; many experts recommend additional therapy with Benzathine PCN G 2.4 MU IM weekly for 3 doses after completion of IV therapy</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="438338" conceptname="Meningococcal meningitis">Meningococcal meningitis</span> and/or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span></td>
<td align="left"></td>
<td align="left">24 million units/day as 2 million units every 2 hours</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Pediatric patients</h2>
<p class="First">This product should not be administered to patients requiring less than one million units per dose (see <span class="Bold"><a href="#precautions-ped-use"> Precautions-Pediatric Use</a></span>).</p>
<table width="75%">
<col align="left" valign="top" width="45%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="45%">
<thead><tr class="First Last">
<th align="center">CLINICAL INDICATION</th>
<th align="left"></th>
<th align="center">DOSAGE</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of streptococci (including <span class="Italics">S. pneumoniae</span>) and meningococcus<br>
</td>
<td align="left"></td>
<td align="left">150,000–300,000 units/kg/day divided in equal doses every 4–6 hours; duration depends on infecting organism and type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of pneumococcus and meningococcus</td>
<td align="left"></td>
<td align="left">250,000 units/kg/day divided in equal doses every 4 hours for 7–14 days depending on the infecting organism (maximum dose of 12–20 million units/day)<br>
</td>
</tr>
<tr>
<td align="left">Disseminated Gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br>
</td>
<td align="left"></td>
<td align="left">Weight less than 45 kg:</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></td>
<td align="left"></td>
<td align="left">100,000 units/kg/day in 4 equally divided doses for 7–10 days<br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span></td>
<td align="left"></td>
<td align="left">250,000 units/kg/day in equal doses every 4 hours for 10–14 days<br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></td>
<td align="left"></td>
<td align="left">250,000 units/kg/day in equal doses every 4 hours for 4 weeks<br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span></td>
<td align="left"></td>
<td align="left">Weight 45 kg or greater: 10 million units/day in equally divided doses with the duration of therapy depending on the type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> (congenital and neurosyphilis) after the newborn period</td>
<td align="left"></td>
<td align="left">200,000–300,000 units/kg/day (administered as 50,000 units/kg every 4–6 hours) for 10–14 days<br>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> (adjunctive therapy to antitoxin and for prevention of the carrier state)<br>
</td>
<td align="left"></td>
<td align="left">150,000–250,000 units/kg/day in equal doses every 6 hours for 7–10 days</td>
</tr>
<tr class="Last">
<td align="left">Rat-bite <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; Haverhill <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (with <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> caused by <span class="Italics">S. moniliformis</span>)</td>
<td align="left"></td>
<td align="left">150,000–250,000 units/kg/day in equal doses every 4 hours for 4 weeks<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Penicillin G is relatively nontoxic, and dosage adjustments are generally required only in cases of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The recommended dosage regimens are as follows:</p>
<p>Creatinine clearance less than 10 mL/min/1.73m<span class="Sup">2</span>; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 8–10 hours.</p>
<p>Uremic patients with a creatinine clearance greater than 10 mL/min/1.73m<span class="Sup">2</span>; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 4–5 hours. Additional dosage modification should be made in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>For most acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for Group A β-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> should be maintained for atleast 10 days to reduce the risk of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2>Reconstitution</h2>
<p class="First">The following table shows the amount of solvent required for solution of various concentrations:</p>
<table width="75%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="4%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="4%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="4%">
<col align="center" valign="top" width="22%">
<thead><tr class="First Last">
<th align="center">Approx. Desired Concentration (units/mL)</th>
<th align="center"></th>
<th align="center">Approx. Volume (mL) 1,000,000 units</th>
<th align="center"></th>
<th align="center">Solvent for Vial of 5,000,000 units</th>
<th align="center"></th>
<th align="center">Infusion Only 20,000,000 units</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">50,000</td>
<td align="center"></td>
<td align="center">20.0</td>
<td align="center"></td>
<td align="center">–</td>
<td align="center"></td>
<td align="center">–</td>
</tr>
<tr>
<td align="center">100,000</td>
<td align="center"></td>
<td align="center">10.0</td>
<td align="center"></td>
<td align="center">–</td>
<td align="center"></td>
<td align="center">–</td>
</tr>
<tr>
<td align="center">250,000</td>
<td align="center"></td>
<td align="center">4.0</td>
<td align="center"></td>
<td align="center">18.2</td>
<td align="center"></td>
<td align="center">75.0</td>
</tr>
<tr>
<td align="center">500,000</td>
<td align="center"></td>
<td align="center">1.8</td>
<td align="center"></td>
<td align="center">8.2</td>
<td align="center"></td>
<td align="center">33.0</td>
</tr>
<tr>
<td align="center">750,000</td>
<td align="center"></td>
<td align="center">–</td>
<td align="center"></td>
<td align="center">4.8</td>
<td align="center"></td>
<td align="center">–</td>
</tr>
<tr class="Last">
<td align="center">1,000,000</td>
<td align="center"></td>
<td align="center">–</td>
<td align="center"></td>
<td align="center">3.2</td>
<td align="center"></td>
<td align="center">11.5</td>
</tr>
</tbody>
</table>
<p>When the required volume of solvent is greater than the capacity of the vial, the penicillin can be dissolved by first injecting only a portion of the solvent into the vial, then withdrawing the resultant solution and combining it with the remainder of the solvent in a larger sterile container.</p>
<p>Buffered Pfizerpen (penicillin G potassium) for Injection is highly water soluble. It may be dissolved in small amounts of Water for Injection, or Sterile Isotonic Sodium Chloride Solution for Parenteral Use. All solutions should be stored in a refrigerator. When refrigerated, penicillin solutions may be stored for seven days without significant loss of potency.</p>
<p>Buffered Pfizerpen for Injection may be given intramuscularly or by continuous intravenous drip for dosages of 500,000, 1,000,000, or 5,000,000 units. It is also suitable for intrapleural, intraarticular, and other local instillations.</p>
<p>THE 20,000,000 UNIT DOSAGE MAY BE ADMINISTERED BY INTRAVENOUS INFUSION ONLY.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4.1"></a><p></p>
<h3>(1) Intramuscular Injection</h3>
<p class="First">Keep total volume of injection small. The intramuscular route is the preferred route of administration. Solutions containing up to 100,000 units of penicillin per mL of diluent may be used with a minimum of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>. Greater concentration of penicillin G per mL is physically possible and may be employed where therapy demands. When large dosages are required, it may be advisable to administer aqueous solutions of penicillin by means of continuous intravenous drip.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4.2"></a><p></p>
<h3>(2) Continuous Intravenous Drip</h3>
<p class="First">Determine the volume of fluid and rate of its administration required by the patient in a 24 hour period in the usual manner for fluid therapy, and add the appropriate daily dosage of penicillin to this fluid. For example, if an adult patient requires 2 liters of fluid in 24 hours and a daily dosage of 10 million units of penicillin, add 5 million units to 1 liter and adjust the rate of flow so the liter will be infused in 12 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4.3"></a><p></p>
<h3>(3) Intrapleural or Other Local Infusion</h3>
<p class="First">If fluid is aspirated, give infusion in a volume equal to ¼ or ½ the amount of fluid aspirated, otherwise, prepare as for intramuscular injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4.4"></a><p></p>
<h3>(4) Intrathecal Use</h3>
<p class="First">The intrathecal use of penicillin in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> must be highly individualized. It should be employed only with full consideration of the possible irritating effects of penicillin when used by this route. The preferred route of therapy in bacterial meningitides is intravenous, supplemented by intramuscular injection.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>Sterile solution may be left in refrigerator for one week without significant loss of potency.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Buffered Pfizerpen® (penicillin G potassium) for Injection is available in vials containing respectively 5,000,000 units × 10's (NDC 0049-0520-83) and 20,000,000 units × 1's (NDC 0049-0530-28); buffered with sodium citrate and citric acid to an optimum pH.</p>
<p>Each million units contains approximately 6.8 milligrams of sodium (0.3 mEq) and 65.6 milligrams of potassium (1.68 mEq).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Store the dry powder below 86°F (30°C).</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>References</h1>
<p class="First">1. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Ninth Edition</span>. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</p>
<p>2. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement</span>, CLSI document M100-S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013.</p>
<p>3. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline- Second Edition</span>. CLSI document M45-A2, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA, 2010.</p>
<p>4. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition</span>. CLSI document M02-A11, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</p>
<p>5. American Heart Association, 1977. Prevention of <span class="product-label-link" type="condition" conceptid="4116649" conceptname="Bacterial endocarditis">bacterial endocarditis</span>. Circulation. 56:139A-143A.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com</p>
<p><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320&amp;name=pfizerpen-02.jpg"></p>
<p>LAB-0200-4.0</p>
<p>October 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Five Million Unit Vial Label</h1>
<p class="First"><span class="Bold">5<br>FIVE<br>MILLION UNITS</span></p>
<p>NDC 0049-0520-83</p>
<p>Buffered<br><span class="Bold">Pfizerpen</span><span class="Sup">®</span><br>(penicillin G potassium)<br>For Injection</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Five Million Unit Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320&amp;name=pfizerpen-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Five Million Unit Vial Carton</h1>
<p class="First"><span class="Bold">10 Vials<br>Buffered</span></p>
<p>NDC 0049-0520-83<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">Pfizerpen</span><span class="Sup">®</span><br>(penicillin G potassium)</p>
<p>For Injection</p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<p><span class="Bold">5<br>FIVE<br>MILLION UNITS</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Five Million Unit Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320&amp;name=pfizerpen-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Twenty Million Unit Vial Label</h1>
<p class="First"><span class="Bold">20<br>TWENTY<br>MILLION UNITS</span></p>
<p>NDC 0049-0530-28</p>
<p>Buffered<br><span class="Bold">Pfizerpen</span><span class="Sup">®</span><br>(penicillin G potassium)<br>For Injection</p>
<p>For Intravenous Infusion Only</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Twenty Million Unit Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320&amp;name=pfizerpen-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Twenty Million Unit Vial Carton</h1>
<p class="First"><span class="Bold">20<br>TWENTY<br>MILLION UNITS</span></p>
<p>NDC 0049-0530-28<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">Buffered</span></p>
<p><span class="Bold">Pfizerpen</span><span class="Sup">®</span><br>(penicillin G potassium)</p>
<p><span class="Bold">For Injection</span></p>
<p>For Intravenous Infusion Only</p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Twenty Million Unit Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320&amp;name=pfizerpen-06.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PFIZERPEN 		
					</strong><br><span class="contentTableReg">penicillin g potassium powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0049-0520</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR, INTRAPLEURAL, INTRATHECAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PENICILLIN G POTASSIUM</strong> (PENICILLIN G) </td>
<td class="formItem">PENICILLIN G</td>
<td class="formItem">5000000 [iU]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0049-0520-83</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA060657</td>
<td class="formItem">06/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PFIZERPEN 		
					</strong><br><span class="contentTableReg">penicillin g potassium powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0049-0530</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PENICILLIN G POTASSIUM</strong> (PENICILLIN G) </td>
<td class="formItem">PENICILLIN G</td>
<td class="formItem">20000000 [iU]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0049-0530-28</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA060657</td>
<td class="formItem">06/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Roerig
							(829076996)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Haupt Pharma Latina S.r.l.</td>
<td class="formItem"></td>
<td class="formItem">338690598</td>
<td class="formItem">ANALYSIS(0049-0530, 0049-0520), MANUFACTURE(0049-0530, 0049-0520), PACK(0049-0530, 0049-0520)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ACS Dobfar S.p.A.</td>
<td class="formItem"></td>
<td class="formItem">429243025</td>
<td class="formItem">API MANUFACTURE(0049-0530, 0049-0520)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">ANALYSIS(0049-0530, 0049-0520)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4f711558-a54a-482f-8dbb-ccbbcf197e28</div>
<div>Set id: d8aaefb6-3f7d-4bc5-b40a-1c58c3054320</div>
<div>Version: 9</div>
<div>Effective Time: 20141121</div>
</div>
</div> <div class="DistributorName">Roerig</div></p>
</body></html>
